Scholarlink

<p>Non-living cell therapeutics have become crucial for treating diverse disease conditions. However, ineffective manufacturing processes, significant cellular content loss and structural damage reduce therapeutic efficacy. Here we present a translational approach for designing ‘off-the-shelf’ highly efficient active lyophilized tannic-acid-engineered non-living cells (HealTEC) with distinct features. Our strategy is customizable and integrates cellular function enhancement, high-dose tannic acid-induced cell inactivation, low-temperature cellular matter condensation and advanced lyophilization. By leveraging it, we engineer mesenchymal stem cell-derived HealTEC as a bio-reservoir platform, enabling formulations enriched in immunomodulatory factors for ulcerative colitis, enriched in angiogenic factors for hindlimb ischaemia or loaded with drug nanoparticles for asthma. Importantly, the HealTEC formulations exhibit high therapeutic stability after long-term storage at mild conditions. Furthermore, HealTEC injections induce much lower immunogenicity than living cell injections, both in the short term and long term. HealTEC technology presents the potential for upscaling cell manufacture, commercialization and reshaping worldwide clinical demands.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Off‑the‑shelf, engineered non-living stem cell strategy for advancing cellular therapies

  • 期刊论文

  • 发表日期：

    2026年6月29日

查看全文
  • Tiep Tien Nguyen,
  • Nhu-Nam Nguyen,
  • Linh Nguyen,
  • Kim-Phuong Phan,
  • Junhyeung Park,
  • Jong-Hyuk Sung,
  • Simmyung Yook,
  • Hu-Lin Jiang,
  • Jee-Heon Jeong

摘要

Non-living cell therapeutics have become crucial for treating diverse disease conditions. However, ineffective manufacturing processes, significant cellular content loss and structural damage reduce therapeutic efficacy. Here we present a translational approach for designing ‘off-the-shelf’ highly efficient active lyophilized tannic-acid-engineered non-living cells (HealTEC) with distinct features. Our strategy is customizable and integrates cellular function enhancement, high-dose tannic acid-induced cell inactivation, low-temperature cellular matter condensation and advanced lyophilization. By leveraging it, we engineer mesenchymal stem cell-derived HealTEC as a bio-reservoir platform, enabling formulations enriched in immunomodulatory factors for ulcerative colitis, enriched in angiogenic factors for hindlimb ischaemia or loaded with drug nanoparticles for asthma. Importantly, the HealTEC formulations exhibit high therapeutic stability after long-term storage at mild conditions. Furthermore, HealTEC injections induce much lower immunogenicity than living cell injections, both in the short term and long term. HealTEC technology presents the potential for upscaling cell manufacture, commercialization and reshaping worldwide clinical demands.